Products KRN125(pegfilgrastim), PLR001(plerixafor) + KRN8601(filgrastim), PLR001(plerixafor)
KRN125(pegfilgrastim), PLR001(plerixafor) + KRN8601(filgrastim), PLR001(plerixafor) Phase 2 Completed ⚡ Active Multiple Myeloma and Malignant Lymphoma
Multiple Myeloma and Malignant Lymphoma
Sep 1, 2021 → Oct 25, 2022
About KRN125(pegfilgrastim), PLR001(plerixafor) + KRN8601(filgrastim), PLR001(plerixafor) KRN125(pegfilgrastim), PLR001(plerixafor) + KRN8601(filgrastim), PLR001(plerixafor) is a phase 2 stage product being developed by Kyowa Kirin for Multiple Myeloma and Malignant Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT05007652. Target conditions include Multiple Myeloma and Malignant Lymphoma.
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT05007652 Phase 2 Completed Sep 1, 2021 Oct 25, 2022 Multiple Myeloma and Malignant Lymphoma
Competing Products 20 competing products in Multiple Myeloma and Malignant Lymphoma
See all competitors Product Company Stage Hype Score Placebo + Pirtobrutinib Eli Lilly Phase 2 Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide Eli Lilly Phase 1/2 NEX-20A Nanexa AB Phase 1 agenT-797 MiNK Therapeutics Phase 1 Duloxetine Hydrochloride (HCI) + Placebo Eli Lilly Phase 3 Temferon Genenta Science Phase 1/2 CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab) Celltrion Phase 3 CT-P53 + US-Ocrevus + EU-Ocrevus Celltrion Phase 3 CS-0777 tablets + CS-0777 tablets + CS-0777 tablets Daiichi Sankyo Phase 1 ASP7487, Velcade, Dexamethasone Astellas Pharma Phase 1/2 PHE885 Novartis Phase 2 Mirabegron + Placebo Astellas Pharma Approved Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + Placebo Astellas Pharma Approved Denileukin Diftitox (Ontak) Eisai Phase 1 Palonosetron Eisai Phase 2 BIW-8962 Kyowa Kirin Phase 1 KW-2478 + Bortezomib Kyowa Kirin Phase 1/2 ONO-2808 + Placebo Ono Pharmaceutical Phase 2 KW-2478 Kyowa Kirin Phase 1 ONO-4641 + ONO-4641 + ONO-4641 + ONO-4641 placebo Ono Pharmaceutical Phase 2
Other Products from Kyowa Kirin